Bryan Li

692 total citations
19 papers, 219 citations indexed

About

Bryan Li is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Bryan Li has authored 19 papers receiving a total of 219 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 9 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Bryan Li's work include Glioma Diagnosis and Treatment (10 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Chromatin Remodeling and Cancer (4 papers). Bryan Li is often cited by papers focused on Glioma Diagnosis and Treatment (10 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Chromatin Remodeling and Cancer (4 papers). Bryan Li collaborates with scholars based in Canada, United States and China. Bryan Li's co-authors include Meredith S. Irwin, Dimitrios Dimitriadis, Andreas Stolcke, Michael Ohh, Àngel Blanch, Ian R. Watson, O. Roche, Roland Leung, Annie Huang and Jeffrey Sum Lung Wong and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and Acta Neuropathologica.

In The Last Decade

Bryan Li

19 papers receiving 214 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bryan Li Canada 8 86 68 43 35 33 19 219
Angelo Dipasquale Italy 9 55 0.6× 66 1.0× 80 1.9× 15 0.4× 36 1.1× 23 217
Qiao Zhou China 8 39 0.5× 19 0.3× 88 2.0× 9 0.3× 110 3.3× 15 272
Mary Linton B. Peters United States 10 34 0.4× 138 2.0× 6 0.1× 55 1.6× 52 1.6× 34 301
Qiong Liang China 8 48 0.6× 57 0.8× 4 0.1× 5 0.1× 34 1.0× 20 201
Zheng Su China 8 96 1.1× 36 0.5× 11 0.3× 16 0.5× 9 0.3× 15 231
Marika Reinius United Kingdom 6 39 0.5× 46 0.7× 9 0.2× 10 0.3× 38 1.2× 11 192
Jarey H. Wang United States 8 52 0.6× 43 0.6× 9 0.2× 5 0.1× 40 1.2× 13 184
Eugene Vaios United States 11 20 0.2× 57 0.8× 102 2.4× 20 0.6× 107 3.2× 31 246
Judy Nguyen United States 7 66 0.8× 79 1.2× 7 0.2× 6 0.2× 24 0.7× 14 244

Countries citing papers authored by Bryan Li

Since Specialization
Citations

This map shows the geographic impact of Bryan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan Li more than expected).

Fields of papers citing papers by Bryan Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan Li. The network helps show where Bryan Li may publish in the future.

Co-authorship network of co-authors of Bryan Li

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan Li. A scholar is included among the top collaborators of Bryan Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan Li. Bryan Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Mazewski, Claire, Sarah Leary, Guolian Kang, et al.. (2025). Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children’s Oncology Group. Neuro-Oncology. 27(10). 2726–2737. 3 indexed citations
2.
Benhamida, Jamal, Deqin Ma, Christopher William, et al.. (2023). Recurrent TRAK1::RAF1 Fusions in pediatric low‐grade gliomas. Brain Pathology. 33(5). e13185–e13185. 3 indexed citations
3.
Karajannis, Matthias A., Bryan Li, Mark M. Souweidane, et al.. (2022). YAP1-MAML2 fusion in a pediatric NF2-wildtype intraparenchymal brainstem schwannoma. Acta Neuropathologica Communications. 10(1). 117–117. 5 indexed citations
4.
Rubens, Jeffrey, Craig Erker, Ben Ho, et al.. (2022). Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board. Neuro-Oncology Advances. 4(1). vdac092–vdac092. 1 indexed citations
5.
Lam, Tai‐Chung, Cheuk‐Wai Choi, Kwok-Keung Yuen, et al.. (2021). Integrative Palliative Care Service Model Improved End-of-Life Care and Overall Survival of Advanced Cancer Patients in Hong Kong: A Review of Ten-Year Territory-Wide Cohort. Journal of Palliative Medicine. 24(9). 1314–1320. 9 indexed citations
6.
Wong, Jeffrey Sum Lung, Vikki Tang, Bryan Li, et al.. (2021). Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.. Journal of Clinical Oncology. 39(3_suppl). 330–330. 19 indexed citations
7.
Wong, Jeffrey Sum Lung, Ryohichi Sugimura, Ka‐On Lam, et al.. (2021). Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers. 13(8). 1949–1949. 36 indexed citations
8.
Leung, Thomas W. T., Vikki Tang, Bryan Li, et al.. (2021). The use of cabozantinib in advanced hepatocellular carcinoma (HCC): Hong Kong multi-center experience.. Journal of Clinical Oncology. 39(3_suppl). 316–316. 2 indexed citations
9.
Li, Bryan, Peter C. Burger, Alexander R. Judkins, et al.. (2020). PATH-24. MOLECULAR CLASSIFICATION OF HIGH RISK INFANT EMBRYONAL BRAIN TUMORS ENROLLED IN THE ACNS0334 TRIAL: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP. Neuro-Oncology. 22(Supplement_3). iii429–iii429. 1 indexed citations
10.
Liu, Anthony P. Y., Brent A. Orr, Bryan Li, et al.. (2020). WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?. Acta Neuropathologica. 140(4). 595–597. 5 indexed citations
11.
Li, Bryan, et al.. (2020). Pediatric embryonal brain tumors in the molecular era. Expert Review of Molecular Diagnostics. 20(3). 293–303. 7 indexed citations
12.
Mazewski, Claire, Guolian Kang, Stewart J. Kellie, et al.. (2020). MBCL-34. EFFICACY OF METHOTREXATE (MTX) ACCORDING TO MOLECULAR SUB-TYPE IN YOUNG CHILDREN WITH MEDULLOBLASTOMA (MB): A REPORT FROM CHILDREN’S ONCOLOGY GROUP PHASE III TRIAL ACNS0334. Neuro-Oncology. 22(Supplement_3). iii396–iii396. 13 indexed citations
13.
14.
Li, Bryan, Dimitrios Dimitriadis, & Andreas Stolcke. (2019). Acoustic and Lexical Sentiment Analysis for Customer Service Calls. 5876–5880. 33 indexed citations
15.
Yau, Thomas Cheung, Vikki Tang, Roland Leung, et al.. (2019). Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 37(4_suppl). 365–365. 3 indexed citations
16.
Yau, Thomas Cheung, Vikki Tang, Joanne Chiu, et al.. (2019). Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients.. Journal of Clinical Oncology. 37(4_suppl). 361–361. 2 indexed citations
17.
Sin‐Chan, Patrick, Bryan Li, Ben Ho, Adriana Fonseca, & Annie Huang. (2018). Molecular Classification and Management of Rare Pediatric Embryonal Brain Tumors. Current Oncology Reports. 20(9). 69–69. 12 indexed citations
18.
Owens, Cormac, Bryan Li, Karen E. Thomas, & Meredith S. Irwin. (2016). Surveillance imaging and radiation exposure in the detection of relapsed neuroblastoma. Pediatric Blood & Cancer. 63(10). 1786–1793. 17 indexed citations
19.
Watson, Ian R., Bryan Li, O. Roche, et al.. (2009). Chemotherapy induces NEDP1-mediated destabilization of MDM2. Oncogene. 29(2). 297–304. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angelo Dipasquale Breakdown of academic impact, for papers by Qiao Zhou Breakdown of academic impact, for papers by Mary Linton B. Peters Breakdown of academic impact, for papers by Qiong Liang Breakdown of academic impact, for papers by Zheng Su Breakdown of academic impact, for papers by Marika Reinius Breakdown of academic impact, for papers by Jarey H. Wang Breakdown of academic impact, for papers by Eugene Vaios Breakdown of academic impact, for papers by Judy Nguyen
Rankless by CCL
2026